Literature DB >> 20548337

Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant.

A R Smith1, E Gulbahce, M J Burke, Q Cao, M L Macmillan, J Tolar, P J Orchard, B R Blazar, K S Baker, J E Wagner, M R Verneris.   

Abstract

Pulmonary cytolytic thrombi (PCT) is an uncommon complication after hematopoietic cell transplantation. Although the pathogenesis is unknown, patients typically respond to systemic corticosteroid treatment. Considering corticosteroids may impair GVL reactions, we reviewed the records of 324 pediatric patients who received a transplant for leukemia and compared the outcomes of those with PCT (n=14) to those without PCT (n=310). PCT patients had a significantly more acute GVHD (aGVHD) and chronic GVHD (cGVHD). Though 3-year non-relapse mortality and OS were similar, there was significantly less relapse in patients with PCT compared to those without PCT (0 vs 28%, P=0.02), regardless of the presence or absence of aGVHD. In multivariate analysis, grade II-IV aGVHD (P=0.02), cGVHD (P=0.01) and development of PCT (P<0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse.

Entities:  

Mesh:

Year:  2010        PMID: 20548337      PMCID: PMC3556271          DOI: 10.1038/bmt.2010.119

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation.

Authors:  J P Woodard; E Gulbahce; M Shreve; M Steiner; C Peters; S Hite; N K Ramsay; T DeFor; K S Baker
Journal:  Bone Marrow Transplant       Date:  2000-02       Impact factor: 5.483

2.  Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description.

Authors:  Antoinette Peters; J Carlos Manivel; Michelle Dolan; H Evin Gulbahce; K Scott Baker; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2005-06       Impact factor: 5.742

Review 3.  Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.

Authors:  David Valcárcel; Rodrigo Martino; Jose L Piñana; Jorge Sierra
Journal:  Curr Opin Oncol       Date:  2009-06       Impact factor: 3.645

4.  Non-parametric inference for cumulative incidence functions in competing risks studies.

Authors:  D Y Lin
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

5.  Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.

Authors:  Angela R Smith; K Scott Baker; Todd E Defor; Michael R Verneris; John E Wagner; Margaret L Macmillan
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

Review 6.  Chronic graft-versus-host disease.

Authors:  Mitchell E Horwitz; Keith M Sullivan
Journal:  Blood Rev       Date:  2005-04-07       Impact factor: 8.250

7.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

Authors:  Margaret L MacMillan; Daniel J Weisdorf; John E Wagner; Todd E DeFor; Linda J Burns; Norma K C Ramsay; Stella M Davies; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

8.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

Authors:  Michael R Verneris; Claudio G Brunstein; Juliet Barker; Margaret L MacMillan; Todd DeFor; David H McKenna; Michael J Burke; Bruce R Blazar; Jeffrey S Miller; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Blood       Date:  2009-08-25       Impact factor: 22.113

9.  Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).

Authors:  Mukta Arora; Sriharsha Nagaraj; John E Wagner; Juliet N Barker; Claudio G Brunstein; Linda J Burns; Todd E Defor; Margaret L McMillan; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-27       Impact factor: 5.742

10.  Pulmonary cytolytic thrombi: unusual complication of hematopoietic stem cell transplantation.

Authors:  Ian J Morales; Peter M Anderson; Henry D Tazelaar; Mark E Wylam
Journal:  J Pediatr Hematol Oncol       Date:  2003-01       Impact factor: 1.289

View more
  1 in total

1.  Neuroregeneration and functional recovery after stroke: advancing neural stem cell therapy toward clinical application.

Authors:  Yang Jiao; Yu-Wan Liu; Wei-Gong Chen; Jing Liu
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.